Unnati Pharmax

Distoside® Tablets
Composition: Praziquantel Tablets
International Trade Name: Distocide®

Distoside® is a high-quality Praziquantel tablet formulation, comparable to the internationally recognized anthelmintic brand Distocide®. Manufactured in WHO-GMP certified facilities, Distoside® Tablets are supplied by trusted pharmaceutical exporters from India to support global parasitic disease control and treatment programs.

Praziquantel is a broad-spectrum anthelmintic agent effective against a wide range of trematodes (flukes) and cestodes (tapeworms). It works by increasing the permeability of parasite cell membranes to calcium ions, causing rapid muscular contraction, paralysis, and subsequent death of the parasites, which are then eliminated by the host immune system.

Distoside® Praziquantel Tablets are primarily indicated for the treatment of schistosomiasis, clonorchiasis, opisthorchiasis, paragonimiasis, taeniasis, diphyllobothriasis, and other fluke and tapeworm infections. The tablets are widely used in hospital settings, infectious disease programs, and mass deworming initiatives, especially in endemic regions.

Distoside Tablets, praziquantel tablets, Distocide® equivalent, anthelmintic medicine, schistosomiasis treatment, fluke and tapeworm infection therapy, WHO-GMP pharmaceutical exporter India, and antiparasitic tablet manufacturer India.

Distoside® Tablets are manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent efficacy, safety, and bioavailability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, clinics, government health programs, NGOs, and international pharmaceutical distributors worldwide.

Prazivac® 600 Tablets
Composition: Praziquantel Tablets 600 mg
International Trade Name: Praziquantel

Prazivac 600 is a high-quality Praziquantel 600 mg Tablet, a broad-spectrum anthelmintic medicine widely used for the treatment of schistosomiasis and other trematode and cestode infections. Praziquantel is internationally recognized as a first-line therapy in many parasitic disease control programs. Prazivac Tablets are manufactured in WHO-GMP certified facilities and supplied by trusted pharmaceutical exporters from India to serve regulated global markets.

Praziquantel works by increasing the permeability of parasite cell membranes to calcium ions, causing severe muscle contraction, paralysis, and subsequent death of the parasite. This targeted mechanism provides high efficacy against susceptible parasites while maintaining a favorable safety profile when used under medical supervision.

Prazivac Praziquantel 600 mg Tablets are primarily indicated for the treatment of schistosomiasis (all major species) and infections caused by tapeworms and flukes, including clonorchiasis, opisthorchiasis, and paragonimiasis, as prescribed by healthcare professionals. The 600 mg strength allows for standardized dosing and convenient administration in both individual treatment and mass drug administration programs.

Praziquantel 600 mg tablets, Prazivac 600 tablets, anthelmintic medicine, schistosomiasis treatment, tapeworm infection therapy, parasitic disease control, WHO-GMP pharmaceutical exporter India.

Prazivac® 600 Tablets are produced under stringent GMP and quality assurance systems to ensure consistent potency, safety, and stability. The product is supplied in tamper-evident, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, clinics, public health programs, NGOs, government tenders, and international pharmaceutical distributors worldwide.

Botox® 100 Units Injection
Composition: Botulinum Toxin Type A (Ph. Eur.)
International Trade Name: Botox®

Botox 100 is a premium Botulinum Toxin Type A (Ph. Eur.) Injection, internationally recognized under the trade name Botox®. It is a highly purified neurotoxin preparation widely used in medical, therapeutic, and aesthetic indications. Manufactured and quality-tested in accordance with European Pharmacopoeia (Ph. Eur.) and international GMP standards, Botox 100 Units Injection is supplied through regulated pharmaceutical channels to meet global clinical requirements.

Botulinum Toxin Type A acts by blocking the release of acetylcholine at the neuromuscular junction, leading to temporary and localized muscle relaxation. This precise mechanism makes Botox an established treatment for a broad range of neuromuscular disorders as well as cosmetic procedures, with predictable efficacy and a well-documented safety profile when administered by trained healthcare professionals.

Botox 100 Units Injection is primarily indicated for the treatment of neurological and muscular conditions such as cervical dystonia, blepharospasm, hemifacial spasm, spasticity, and chronic migraine. In aesthetic medicine, it is widely used for the temporary improvement of moderate to severe facial lines and wrinkles, including glabellar lines, forehead lines, and crow’s feet.

Botulinum toxin type A injection, Botox 100 units, neuromuscular disorder treatment, cosmetic injectable, wrinkle reduction therapy, medical aesthetics product, GMP-certified biologics exporter.

Botox® 100 Units Injection is manufactured under stringent quality control and biologics manufacturing standards, ensuring consistent potency, purity, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, neurology clinics, pain management centers, aesthetic clinics, and international pharmaceutical distributors worldwide.

Hyalugel® Plus Gel
Composition: Hyaluronic Acid Oral Gel
International Trade Name: Hyalugel®

Hyalugel Plus is a high-quality Hyaluronic Acid Gel, internationally recognized under the trade name Hyalugel®. It is a topical oral mucosal gel specifically formulated to support healing, hydration, and protection of the oral tissues. Hyalugel Plus is widely used in dental and oral care practice for the management of mouth ulcers, gingivitis, periodontitis, oral lesions, and post-dental procedure care. The product is manufactured in compliance with international quality standards and supplied through trusted pharmaceutical channels.

Hyaluronic acid is a naturally occurring biopolymer with exceptional moisturizing, tissue-repair, and anti-inflammatory properties. When applied topically, Hyalugel Plus forms a protective film over the oral mucosa, helping to reduce pain, promote faster tissue regeneration, and maintain optimal moisture balance in the affected area.

Hyalugel Plus Hyaluronic Acid Gel is primarily indicated for the treatment of aphthous ulcers, oral mucositis, gingivitis, periodontal disease, and for post-operative care following dental procedures such as extractions, implants, and scaling. It is also beneficial in cases of traumatic oral lesions and irritation caused by orthodontic appliances or dentures.

Hyaluronic acid oral gel, Hyalugel Plus gel, mouth ulcer treatment, oral mucosal healing gel, dental care gel, gingivitis treatment, pharmaceutical exporter.

Hyalugel® Plus Gel is produced under stringent quality control systems to ensure safety, stability, and consistent performance. The gel is supplied in hygienic, patient-friendly, tamper-evident packaging, making it suitable for use in dental clinics, hospitals, pharmacies, and international pharmaceutical distribution markets.

Clindamycin Capsule 300 mg
Composition: Clindamycin 300 mg Capsules
International Trade Name: Dalacin®

Clindamycin Capsule 300 mg is a high-quality oral antibiotic formulation containing clindamycin, a well-established lincosamide antibacterial agent internationally marketed under the trade name Dalacin®. Manufactured in WHO-GMP certified facilities, Clindamycin 300 mg Capsules are supplied by trusted pharmaceutical exporters from India to support global antibacterial treatment programs in hospital and outpatient care settings.

Clindamycin exerts its antibacterial action by inhibiting protein synthesis through binding to the 50S ribosomal subunit of susceptible bacteria, effectively controlling the growth of Gram-positive cocci and anaerobic organisms. Clindamycin Capsule 300 mg is primarily indicated for the treatment of serious infections including respiratory tract infections, skin and soft tissue infections, bone and joint infections, intra-abdominal infections, gynecological infections, dental infections, and certain ENT infections. It is also commonly prescribed as an alternative therapy in patients with hypersensitivity to penicillins.

Clindamycin 300 mg capsules, Dalacin® equivalent, lincosamide antibiotic, bacterial infection treatment, anaerobic infection therapy, skin and soft tissue infection medicine, WHO-GMP pharmaceutical exporter India, and antibiotic capsule manufacturer India.

Clindamycin Capsule 300 mg is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent efficacy, safety, and bioavailability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, clinics, pharmacies, government healthcare programs, and international pharmaceutical distributors worldwide.

Obeticholic Acid Tablets
Composition: Obeticholic Acid
International Trade Name: Ocaliva®

Obeticholic Acid Tablets are a high-quality oral farnesoid X receptor (FXR) agonist formulation, equivalent to the internationally recognized brand Ocaliva®. Manufactured in WHO-GMP certified facilities, Obeticholic Acid Tablets are supplied by trusted pharmaceutical exporters from India to support advanced liver disease treatment programs globally.

Obeticholic Acid is a potent semi-synthetic bile acid analog that activates the FXR in the liver and intestines, helping to regulate bile acid synthesis, reduce hepatic inflammation, and improve liver function. It is primarily indicated for the treatment of primary biliary cholangitis (PBC) in adults, particularly in patients who have an inadequate response to ursodeoxycholic acid (UDCA) or who are intolerant to UDCA.

Obeticholic Acid tablets, Ocaliva® equivalent, FXR agonist, primary biliary cholangitis treatment, liver disease therapy, WHO-GMP pharmaceutical exporter India, and hepatology drug manufacturer India.

Obeticholic Acid Tablets are manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and bioavailability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, specialty clinics, government healthcare programs, and international pharmaceutical distributors worldwide.

Atarax® 10 mg Tablets
Composition: Hydroxyzine Hydrochloride Tablets 10 mg
International Trade Name: Atarax®

Atarax 10 is a high-quality Hydroxyzine Hydrochloride 10 mg Tablet, internationally recognized under the trade name Atarax®. It is a first-generation antihistamine with well-established anti-allergic, anxiolytic, and sedative properties. Manufactured in WHO-GMP certified facilities, Atarax Tablets are supplied by trusted pharmaceutical manufacturers and exporters from India to serve global therapeutic markets.

Hydroxyzine hydrochloride acts by blocking histamine H1 receptors, effectively relieving symptoms of allergic conditions such as itching, rash, and urticaria. In addition, its central nervous system depressant activity makes it useful in the short-term management of anxiety and tension, as well as for pre- and post-operative sedation and adjunctive treatment of nausea and vomiting.

Atarax Hydroxyzine Hydrochloride Tablets 10 mg are primarily indicated for the symptomatic relief of anxiety and tension, treatment of pruritus associated with allergic conditions, including chronic urticaria and atopic dermatitis, and as a sedative or anxiolytic adjunct in medical and surgical practice. The 10 mg strength allows for flexible dosing, good tolerability, and suitability for a wide range of patients.

Hydroxyzine hydrochloride 10 mg tablets, Atarax 10 mg tablets, antihistamine tablets, anti-anxiety medication, pruritus relief, allergy treatment tablets, sedative antihistamine, pharmaceutical exporter India.

Atarax® 10 Tablets are produced under stringent GMP and international quality standards, ensuring consistent efficacy, safety, and stability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, clinics, retail pharmacies, mental health centers, and international pharmaceutical distributors worldwide.

Hyalugel® Gel
Composition: Hyaluronic Acid Gel
International Trade Name: Hyalugel®

Hyalugel® is a high-quality Hyaluronic Acid gel formulation designed to promote hydration, tissue repair, and accelerated healing of damaged mucosal and epithelial surfaces. Hyalugel® Gel is widely recognized internationally for its effectiveness in oral, dental, and dermatological care. Manufactured in WHO-GMP certified facilities, Hyalugel® is supplied by trusted pharmaceutical exporters from India to support global medical and dental treatment programs.

Hyaluronic acid is a naturally occurring glycosaminoglycan that plays a vital role in maintaining tissue hydration, elasticity, and wound healing. Hyalugel® works by forming a protective, moisturizing barrier over the affected area, reducing inflammation, relieving discomfort, and enhancing the natural tissue regeneration process. Hyalugel® Gel is primarily indicated for the management of oral ulcers, aphthous stomatitis, gingivitis, periodontitis, post-dental procedure wounds, traumatic lesions, and other inflammatory conditions of the oral mucosa. It may also be used for minor skin wounds, burns, and dermatological lesions as recommended by healthcare professionals.

Hyaluronic Acid gel, Hyalugel® oral gel, wound healing gel, oral ulcer treatment, dental care gel, mucosal healing agent, WHO-GMP pharmaceutical exporter India, and hyaluronic acid gel manufacturer India.

Hyalugel® Gel is manufactured under stringent GMP and quality standards to ensure safety, consistency, and optimal bioavailability. The gel is supplied in secure, hygienic, export-grade packaging with complete regulatory documentation, making it suitable for dental clinics, hospitals, pharmacies, dermatology practices, and international pharmaceutical distributors worldwide.

Canesten-S Cream
Composition: Clotrimazole + Beclomethasone Dipropionate Cream
International Trade Name: Canesten-S®

Canesten-S® is a high-quality combination topical antifungal and anti-inflammatory cream containing Clotrimazole and Beclomethasone Dipropionate, formulated for the effective management of inflammatory fungal skin infections. Canesten-S® is internationally recognized for providing rapid symptomatic relief while simultaneously treating the underlying fungal infection. Manufactured in WHO-GMP certified facilities, Canesten-S Cream is supplied by trusted pharmaceutical exporters from India for global dermatological care programs.

Clotrimazole is a broad-spectrum imidazole antifungal agent that works by inhibiting ergosterol synthesis, leading to disruption of the fungal cell membrane and elimination of pathogenic fungi. Beclomethasone Dipropionate is a potent topical corticosteroid that reduces inflammation, redness, itching, and swelling associated with fungal infections. The synergistic combination in Canesten-S® ensures both effective antifungal action and rapid relief from inflammatory symptoms.

Canesten-S® Cream is primarily indicated for the treatment of tinea infections (tinea corporis, tinea cruris, tinea pedis), cutaneous candidiasis, intertrigo, and other steroid-responsive inflammatory fungal dermatoses where mixed infection and inflammation are present.

Canesten-S Cream, clotrimazole beclomethasone dipropionate cream, antifungal steroid combination, fungal skin infection treatment, tinea infection therapy, dermatology cream, WHO-GMP pharmaceutical exporter India, and topical antifungal manufacturer India.

Canesten-S® Cream is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent efficacy, safety, and skin tolerability. The cream is supplied in secure, hygienic, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, dermatology clinics, pharmacies, government healthcare programs, and international pharmaceutical distributors worldwide.

KROTY-HC® Cream
Composition: Crotamiton & Hydrocortisone Cream
International Trade Name: Crotamiton + Hydrocortisone

KROTY-HC is a high-quality topical dermatological cream combining Crotamiton and Hydrocortisone, two well-established agents used in the management of scabies, pruritus, and inflammatory skin conditions. This synergistic formulation provides both antiparasitic action and anti-inflammatory relief, making it especially effective in parasitic infestations associated with itching and skin irritation. KROTY-HC Cream is manufactured in WHO-GMP certified facilities and supplied by trusted pharmaceutical manufacturers and exporters from India for global dermatology markets.

Crotamiton acts as a scabicidal and antipruritic agent, helping to eliminate scabies mites and relieve intense itching. Hydrocortisone, a mild topical corticosteroid, reduces inflammation, redness, swelling, and allergic skin reactions. Together, these ingredients provide rapid symptomatic relief while supporting skin healing.

KROTY-HC Crotamiton & Hydrocortisone Cream is primarily indicated for the treatment of scabies, pruritic dermatoses, insect bite reactions, and other inflammatory skin conditions associated with itching. The cream formulation ensures easy application, good skin penetration, and improved patient comfort and compliance.

Crotamiton and Hydrocortisone cream, KROTY-HC cream, scabies treatment cream, antipruritic topical cream, dermatology medicine, anti-itch skin cream, pharmaceutical exporter India.

KROTY-HC® Cream is produced under stringent GMP and dermatological quality standards, ensuring consistent efficacy, safety, and stability. The product is supplied in hygienic, tamper-evident, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, dermatology clinics, pharmacies, and international pharmaceutical distributors worldwide.

IMEC-A® Tablets
Composition: Ivermectin & Albendazole Tablets
International Trade Name: Ivermectin + Albendazole

IMEC-A is a high-quality combination antiparasitic tablet containing Ivermectin and Albendazole, two internationally recognized anthelmintic agents with complementary mechanisms of action. This fixed-dose combination is widely used for the treatment and control of mixed parasitic infections, particularly in regions where intestinal helminths and tissue parasites are prevalent. IMEC-A Tablets are manufactured in WHO-GMP certified facilities and supplied by trusted pharmaceutical manufacturers and exporters from India to meet global healthcare needs.

Ivermectin acts by binding to glutamate-gated chloride ion channels in parasite nerve and muscle cells, leading to paralysis and death of susceptible parasites. Albendazole works by inhibiting microtubule formation and glucose uptake in parasites, resulting in energy depletion and eventual parasite elimination. Together, this dual-action therapy provides broad-spectrum efficacy against a wide range of parasitic infections.

IMEC-A Ivermectin & Albendazole Tablets are primarily indicated for the treatment of intestinal worm infestations such as ascariasis, strongyloidiasis, enterobiasis, hookworm infections, and other susceptible nematode infections, as prescribed by healthcare professionals. The combination tablet ensures improved therapeutic coverage, convenient dosing, and better patient compliance.

Ivermectin and Albendazole tablets, IMEC-A tablets, antiparasitic combination medicine, deworming tablets, intestinal helminth treatment, WHO-GMP pharmaceutical exporter India.

IMEC-A® Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent potency, safety, and stability. The product is supplied in tamper-evident, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, clinics, public health deworming programs, pharmacies, and international pharmaceutical distributors worldwide.

EPISERT® Cream
Composition: Sartaconazole Nitrate Cream 2% w/w
International Trade Name: Mycogel® / Zafnack® (Sartaconazole)

EPISERT® Cream is a high-quality Sartaconazole Nitrate 2% w/w topical antifungal formulation, comparable to internationally recognized sartaconazole brands such as Mycogel® and Zafnack®. Manufactured in WHO-GMP certified facilities, EPISERT® Cream is supplied by trusted pharmaceutical exporters from India to support effective dermatological antifungal therapy worldwide.

Sartaconazole nitrate is a modern imidazole antifungal agent with broad-spectrum activity against dermatophytes, yeasts, and molds. It works by inhibiting ergosterol synthesis and directly damaging fungal cell membranes, leading to rapid fungal eradication. Sartaconazole also exhibits anti-inflammatory and antipruritic properties, helping to reduce itching, redness, and irritation commonly associated with fungal skin infections.

EPISERT® Cream 2% w/w is primarily indicated for the treatment of tinea pedis (athlete’s foot), tinea cruris (jock itch), tinea corporis (ringworm), cutaneous candidiasis, pityriasis versicolor, and other superficial fungal infections. Its high efficacy and convenient dosing make it suitable for both acute and recurrent dermatophytosis.

EPISERT Cream, sartaconazole nitrate 2% cream, antifungal dermatology cream, tinea infection treatment, candidiasis therapy, imidazole antifungal agent, WHO-GMP pharmaceutical exporter India, and antifungal cream manufacturer India.

EPISERT® Cream is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and skin tolerability. The cream is supplied in secure, hygienic, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, dermatology clinics, pharmacies, government healthcare programs, and international pharmaceutical distributors worldwide.

IMEC-M® Ivermectin Tablets
Composition: Ivermectin Tablets (strength as per label)
International Trade Name: Ivermectin

IMEC-M is a high-quality Ivermectin Tablet, a broad-spectrum antiparasitic medication widely used in human medicine. Ivermectin is internationally recognized for its effectiveness against a range of parasitic infections, and IMEC-M Tablets are manufactured in WHO-GMP certified facilities to meet global quality and safety standards. The product is supplied by reliable pharmaceutical manufacturers and exporters from India to support regulated international markets.

Ivermectin works by binding selectively to glutamate-gated chloride ion channels in nerve and muscle cells of parasites, leading to paralysis and death of the parasite while exhibiting a favorable safety profile in humans when used as directed. This targeted mechanism makes ivermectin an essential therapy in parasitology and tropical medicine programs worldwide.

IMEC-M Ivermectin Tablets are primarily indicated for the treatment of strongyloidiasis, onchocerciasis, and other susceptible intestinal and ectoparasitic infections as prescribed by healthcare professionals. The tablet formulation ensures accurate dosing, ease of administration, and consistent bioavailability, making it suitable for both institutional and outpatient use.

Ivermectin tablets, IMEC-M tablets, antiparasitic medicine, intestinal parasite treatment, onchocerciasis therapy, strongyloidiasis treatment, WHO-GMP pharmaceutical exporter India.

IMEC-M Tablets are manufactured under stringent GMP and quality control systems to ensure consistent potency, safety, and stability. The product is supplied in tamper-evident, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, clinics, public health programs, pharmacies, and international pharmaceutical distributors.

ONITRAZ SB 130 Capsules
Composition: Itraconazole Capsules 130 mg
International Trade Name: Sporanox®

ONITRAZ SB 130 is a high-quality Itraconazole 130 mg capsule formulation, equivalent to the internationally recognized antifungal brand Sporanox®. Manufactured in WHO-GMP certified facilities, ONITRAZ SB 130 Capsules are supplied by trusted pharmaceutical exporters from India to support global antifungal treatment programs across hospital and outpatient care settings.

Itraconazole is a broad-spectrum triazole antifungal agent that works by inhibiting fungal cytochrome P450–dependent enzymes, thereby disrupting ergosterol synthesis and compromising fungal cell membrane integrity. ONITRAZ SB 130 Capsules are primarily indicated for the treatment of a wide range of systemic and superficial fungal infections, including aspergillosis, histoplasmosis, blastomycosis, candidiasis, onychomycosis (fungal nail infections), dermatophytosis, and other serious mycoses in immunocompromised and immunocompetent patients.

Itraconazole 130 mg capsules, ONITRAZ SB 130, Sporanox® equivalent, antifungal capsule, systemic fungal infection treatment, onychomycosis therapy, triazole antifungal drug, WHO-GMP pharmaceutical exporter India, and antifungal capsule manufacturer India.

ONITRAZ SB 130 Itraconazole Capsules are manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and bioavailability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, clinics, dermatology and infectious disease practices, government healthcare programs, and international pharmaceutical distributors worldwide.